As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.


French German Italian Portuguese Russian

Benign Blood Disorders Services — Clinical Trials

Drug Treatment Study for Children with Hemophilia A

Safety and efficacy of turoctocog alfa pegol (N8-GP) in previously untreated patients with hemophilia A.

Health Literacy and Numeracy in Adolescent Patients with Hemophilia A and B Study

Knowledge and improvement of health literacy and numeracy in adolescent patients with hemophilia A and B.

Hemophilia A or B Treatment Study

A phase 1/2a, open-label, multicenter, dose escalation study to assess the safety, pharmacokinetics and pharmacodynamics profile of a long-acting recombinant Factor VIIa (MOD-5014) in adult men with hemophilia A or B, with or without inhibitors.

Hemophilia A Treatment Study

Prospective, open-label multicenter phase 3b to assess the efficacy and safety of personalized prophylaxis with Human-cl rh-FVIII in previously treated adult with severe hemophilia A.

Molecular and Clinical Biology of von Willebrand Disease Study

Molecular and clinical biology of von Willebrand disease.

National Registry of All Persons with Bleeding and Clotting Disorders

The American Thrombosis and Hemostasis Network (ATHN) national registry of all persons with bleeding and clotting disorders.

Public Health Surveillance for the Prevention of Complications of Bleeding and Clotting Disorders

Public health surveillance for the prevention of complications of bleeding and clotting disorders.

Study of Biomarkers in Hemophilic Arthropathy

Expression of biomarkers in hemophilic arthropathy: Repository of surgical tissue samples and biomarkers in patients with hemophilia.

Study of Hepatitis C Virus Outcomes After Treatment in Patients with Bleeding Disorders

Hepatitis C virus (HCV) outcomes after treatment with direct acting agents (DAA) in patients with bleeding disorders.

Treatment Study for Acute Graft Versus Host Disease

Study of Pregnyl as supplemental treatment for high-risk or hard to treat acute graft versus host disease (GVHD).